Drugs / incyclinide
incyclinide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00003721 | Nov 1998 → Apr 2002 | cancer of unknown primary site | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 1 | NCT00001683 | Oct 1997 → Aug 2003 | lymphoma, melanoma, metastatic malignant neoplasm, renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00004147 | Jul 2000 → Nov 2006 | central nervous system neoplasm | New Approaches to Brain Tumor Therapy Consortium | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00020683 | Mar 2003 → Nov 2005 | HIV infectious disease, Kaposi's sarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | incyclinide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004147 ↗ |
| Known as | COL-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001683 ↗ |
| Known as | Inciclinida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104970 ↗ |
| Known as | Metastat | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104970 ↗ |
| Known as | NSC-683551 | “A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer” NCT00001683 ↗ |
| Action | Inhibit | “By inhibiting MMPs, it is thought that angiogenesis and metastasis can be inhibited.” NCT00001683 ↗ |
| Modality | Small molecule | “COL-3 is a chemically modified tetracycline derivative.” NCT00001683 ↗ |
| Route | Oral | “This is a phase I study of COL-3, an oral matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.” NCT00001683 ↗ |